Tag: global biopharmaceutical CMO market

The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

According to The Business Research Company’s Biopharmaceutical CMO Global Market Report 2024, the biopharmaceutical CMO market is expected to show promising growth in the forecast period.

The biopharmaceutical Contract Manufacturing Organization (CMO) market has witnessed a rapid surge in recent years, reflecting robust growth from $21.72 billion in 2023 to an estimated $24.68 billion in 2024, marking a noteworthy Compound Annual Growth Rate (CAGR) of 13.6%. As we look ahead, the market is set for accelerated growth, reaching an anticipated $41.87 billion by 2028, with a CAGR of 14.1%.

Underlying Factors for Historical Growth

• Increasing demand for biopharmaceuticals
• Globalization of the pharmaceutical industry
• Rise in healthcare expenditure
• Regulatory support
• Surge in research funding

Drivers for Future Growth

The anticipated growth from 2024 to 2028 can be attributed to several key factors:

• Rise in telehealth and remote trials
• Global health initiatives
• Increase in disposable income

Venture Capital Investments as Catalysts for Growth

Impact of Venture Capital Investments

Robust venture capital investments in the life science sector are expected to be a significant driver for the growth of the biopharmaceutical CMO market. The life sciences sector, encompassing organizations conducting research and development on living beings, is witnessing increased investment, leading to heightened manufacturing of biopharmaceuticals.

Illustrative Example from the UK

• In September 2021, the UK saw a record-breaking £1.9 billion ($5.787 billion) raised in venture capital for the life sciences sector within three months.
• This surge in investment is a testament to the sector’s robustness, driving advancements in biopharmaceutical manufacturing.

View More On The Biopharmaceutical CMO Market Report 2024 – https://www.thebusinessresearchcompany.com/report/biopharmaceutical-cmo-global-market-report

Incorporating IoT Technology Advancements

Technological Advancement Trends

Technological advancements, particularly in the realm of the Internet of Things (IoT), are becoming increasingly prominent in the biopharmaceutical CMO market. Major players in the market are leveraging IoT for research and development, enhancing manufacturing processes and overall efficiency.

Innovative Application in Biopharmaceutical Monitoring

• In February 2022, M2Cloud and Thales developed an IoT-based LTE monitoring system for biopharmaceutical monitoring.
• This system allows real-time monitoring of freezers, refrigerated warehouses, and delivery boxes, ensuring temperature and position information verification remotely.
• The incorporation of IoT technology enhances pharmaceutical product safety, exemplifying the industry’s commitment to cutting-edge solutions.

AstraZeneca’s Strategic Acquisition: Reinforcing Rare Disease Medicine Manufacturing

Strategic Acquisition Impact

In July 2021, AstraZeneca, a UK-based biopharmaceutical giant, acquired Alexion Pharmaceuticals, Inc. This strategic move aimed at strengthening AstraZeneca’s presence in immunology and enhancing its capacity to manufacture medicines for rare diseases.

Synergy in Scientific Presence

• The complement-biology platform and substantial pipeline of Alexion Pharmaceuticals provide AstraZeneca with a more robust scientific presence in immunology.
• This acquisition reflects the industry’s focus on diversification and addressing unmet medical needs.

Market Segmentation and Regional Dynamics

Segmentation Highlights

1. By Product:
   • Biologics
   • Biosimilars
2. By Source:
   • Mammalian
   • Non-Mammalian
3. By Service:
   • Manufacturing
   • Fill And Finish Operations
   • Analytical And QC Studies
   • Packaging

Regional Insights

• North America emerged as the largest region in the biopharmaceutical CMO market in 2023.
• Asia-Pacific is poised to be the fastest-growing region in the forecast period, indicating a shift in the global market landscape.

Conclusion: Navigating a Dynamic Landscape of Innovation

As the biopharmaceutical CMO market continues to burgeon, driven by venture capital investments, technological advancements, and strategic acquisitions, the industry stands at the forefront of innovation. Incorporating IoT technology, embracing sustainability, and advancing towards Industry 4.0 underscore the industry’s commitment to efficient and sustainable solutions. With a forecasted trajectory of robust growth, the biopharmaceutical CMO market presents a landscape rich with opportunities, emphasizing the pivotal role it plays in advancing global healthcare and pharmaceutical innovation.

Request A Sample Of The Global Biopharmaceutical CMO Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=7771&type=smp

The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

Phenomenal Market Growth

The assisted reproductive technology market has witnessed a remarkable surge, catapulting from $38.04 billion in 2023 to a projected $45.42 billion in 2024, boasting a compelling Compound Annual Growth Rate (CAGR) of 19.4%. This impressive growth in recent years is attributed to various factors such as an increase in infertility rates, evolving societal norms, heightened awareness, legislative support, and an aging population.

Future Outlook: Rapid Expansion Ahead

The trajectory of growth is set to continue, with the assisted reproductive technology market expected to reach an astounding $91.8 billion by 2028, with a CAGR of 19.2%. Factors fueling this growth include the rising maternal age, escalating demand for same-sex parenting, a surge in medical tourism, the expansion of healthcare infrastructure, and continued research and development initiatives. Notable trends in the forecast period encompass the integration of artificial intelligence (AI), the prevalence of egg freezing, the adoption of single-embryo transfer (SET), preimplantation genetic testing for aneuploidy (PGT-a), and innovative fertility preservation techniques.

Rising Infertility Cases: A Driving Force

Infertility and ART

• The escalating number of infertility cases is a significant catalyst for the assisted reproductive technology market.
• Infertility, affecting both men and women, is diagnosed through the inability to conceive.
• ART, encompassing fertility therapies, plays a pivotal role in addressing infertility concerns.

Major Players in the Market

Key Companies

• Cooper Surgical Inc., Ferring Pharmaceuticals Ltd., Hamilton Thorne Ltd., Merck KGaA, Genea Limited, and more contribute significantly to the market’s growth.
• These companies play crucial roles in advancing assisted reproductive technology through innovative solutions.

View More On The Assisted Reproductive Technology Market Report 2024 – https://www.thebusinessresearchcompany.com/report/assisted-reproductive-technology-global-market-report

PGT-A Alternatives: Advancements in Genetic Testing

Thermo Fisher Scientific Inc.’s Innovation

• In July 2023, Thermo Fisher Scientific Inc. introduced new next-generation sequencing-based options for preimplantation genetic testing-aneuploidy (PGT-A).
• The Ion ReproSeq PGT-A Kit and the Ion AmpliSeq Polyploidy Kit aim to provide valuable genetic insights, increasing the success rate of future pregnancies.
• The Genexus Integrated Sequencer simplifies the research process, offering a comprehensive workflow for aneuploidy analysis.

Strategic Acquisitions Shaping the Landscape

Virtus Health’s Expansion

• In August 2021, Virtus Health Limited acquired Adora Fertility and three-day hospitals from Healius Limited for $45.0 million.
• This strategic move strengthens Virtus Health’s in-vitro fertilization (IVF) portfolio, reinforcing its position in the assisted reproductive technology market.

Market Segmentation and Regional Dominance

Market Segmentation

• Diagnosis: Ovulation Testing, Hysterosalpingography, Ovarian Reserve Testing, Genetic Testing
• Procedure Type: Fresh Non-Donor, Fresh Donor, Frozen Donor, Frozen Non-Donor, Embryo Or Egg Banking
• End-User: Hospitals, Fertility Clinics, Other End-Users

Regional Dynamics

• Europe emerged as the largest region in the assisted reproductive technology market in 2023.

Conclusion: A Landscape of Innovation and Progress

As the assisted reproductive technology market continues its unprecedented growth, it stands at the intersection of technological innovation and addressing societal needs. The surge in infertility cases necessitates advancements in fertility treatments, and major players are actively contributing to this landscape. With innovative genetic testing options, strategic acquisitions, and a robust market segmentation, the assisted reproductive technology market is not just expanding; it’s evolving to meet the diverse needs of individuals and couples seeking fertility solutions. The journey ahead promises groundbreaking developments, ensuring a future where assisted reproductive technology plays a pivotal role in shaping family-building possibilities.

Request A Sample Of The Global Assisted Reproductive Technology Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=5489&type=smp